Genentech has announced that the company submitted a supplementary Biologics License form (sBLA) to the U.S. Food and Drug direction (FDA) for Avastin (bevacizuma as a therapy for people with already treated glioblastoma. If accepted by the FDA, the form would be calculated for an accelerated kudos that allows provisional approve of medicines for cancer or other life-threatening diseases based on previous significant suggesting clinical benefit.

More: - Continued here